PIH5 Respiratory Syncytial Virus (RSV) Prophylaxis in Special Populations  by Paes, B.A. et al.
remission. Significant predictors of medical costs (p0.05) were disease activity,
disease history for both groups, age and employment status for CD subjects and
previous colectomy for UC subjects. CONCLUSIONS: Our analyses show that med-
ical costs of patients with IBD can in part be predicted. However, predictors differ
between CD and UC patients: Disease activity and disease history are the most
important cost predictors, while age and employment status are only important
cost predictors for CD patients.
Individual’s Health – Clinical Outcomes Studies
PIH1
COMPARISON OF UNINTENDED PREGNANCY RATES IN USERS OF 84/7, 21/7,
AND 24/4 ORAL CONTRACEPTIVE REGIMENS
Brewster C1, Howard B2, Lage M3
1Teva Pharmaceuticals, Kansas City, MO, USA, 2Teva Branded Pharmaceutical Products R&D,
Inc., Horsham, PA, USA, 3HealthMetrics Outcomes Research, Groton, CT, USA
OBJECTIVES:To compare pregnancy rates post initiation on oral contraceptive (OC)
users of 84 days levonorgestrel/ethinyl estradiol (EE) 0.15mg/0.03mg tablets plus EE
0.01mg for 7 days in place of placebo (84/7) or, 21 days combined EE/progestin plus
7 days placebo (21/7) or 24 days EE/progestin plus 4 days placebo (24/4) over the
course of 1 year. METHODS: Data for this study were obtained from the US i3
Invision™ Data Mart and spanned the period from January 1, 2006 through March
31, 2010. Patients were included if they received the medication of interest (with
first such receipt identified as index date), were age 15-40 on index date, and had
continuous insurance coverage from index date through 1 year post index date.
Two distinct analyses were performed: 1 comparing pregnancy rates post initiation
on an 84/7 or 21/7 OC and the other comparing pregnancy post initiation on an 84/7
or 24/4 OC. The 84/7 cohort was matched to each of the alternative cohorts of
interest based upon age, sex, region, business type of insurance, insurance product,
and year of index date. RESULTS: There were 5,821 individuals in the 84/7 cohort,
650,816 individuals in the 21/7 cohort, and 111,540 individuals in the 24/4 cohort.
Matching of the 84/7 cohort to each of the alternative cohorts resulted in a success-
ful match rate of over 99% when comparing 84/7 to 21/7 or comparing 84/7 to 24/4.
Pregnancy rates in the 1 year post initiation on an OC were found to be statistically
significantly lower for initiators of 84/7 compared to 21/7 (3.04% vs. 5.12%;
P0.0001) as well as when comparing 84/7 to 24/4 (3.03% vs. 5.28%; P0.0001).
CONCLUSIONS: In this study, pregnancy rates were significantly lower in women
using an 84/7 OC regimen compared to 21/7 or 24/4 regimens.
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CARESS: THE CANADIAN REGISTRY OF SYNAGIS (2005-2010)
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OBJECTIVES: To evaluate the current management of children at high-risk of RSV
infection who received palivizumab prophylaxis and were enrolled in the Canadian
Registry Database.METHODS:A prospective, observational, registry of infants who
received at least 1 dose of palivizumab during the 2005-2010 RSV seasons across 29
sites. Neonatal and demographic data were collected from the parent/caregiver at
enrollment. Data on palivizumab utilization, compliance, and outcomes related to
respiratory illness (RI) events were collected monthly. RESULTS: A total of 7699
infants were enrolled with an average age of 5.46.0 months. Participants were
typically male (56.2%), Caucasian (71.5%) with an average gestational age (GA) of
32.26.0 completed weeks. A total of 5237 (68.0%) infants received palivizumab for
prematurity (35 completed weeks GA without underlying medical disorders), 646
(8.4%) had chronic lung disease, 766 (9.9%) hemodynamically significant congenital
heart disease and 1050 (13.6%) were prophylaxed for other conditions such as CNS
disorders, airway anomalies and cystic fibrosis. Patients received an average of
3.91.6 injections and 30,040 doses overall; 5.5% of patients withdrew from the
study. No direct, drug related serious adverse events were identified. 460 infants
had a total of 541 RI hospitalizations resulting in a hospitalization rate of 6.0%.The
overall RSV positive hospitalization (RSVH) rate was 1.47%. Living with siblings
(p0.046) and having 5 individuals in the household (p0.007) was significantly
associated with time to a patient’s first RSVH. Other risk factors traditionally asso-
ciated with a higher risk for RSV infection, such as gender (p0.429), smoking
(p0.182), daycare attendance (p0.079), age (p0.213), and compliance with treat-
ment (p0.695) were not found to be significantly correlated. CONCLUSIONS: The
RSVH observed from 2005-2010 was 1.4% overall (range 0.3% - 2.1%) and compares
favorably with international registry data despite the steady increase in the num-
ber of Canadian immunized infants with serious underlying medical disorders.
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OBJECTIVES: Paediatric advisory committee guidelines recommend palivizumab
prophylaxis for specific sub-populations of infants at high risk for respiratory syn-
cytial virus (RSV) infection. However, effectiveness of palivizumab may vary across
indications and countries. The objective of our study was to determine hospital-
ization rates for respiratory illness (RIH) and RSV-positive infections (RSVH) follow-
ing prophylaxis and compare rates found in this study with other world-wide data
from published registries. METHODS: Neonatal and demographic data were col-
lected prospectively across 29 national sites as part of an established CAnadian
REgistry for SynagiS (CARESS) database from infants who received 1 dose of
palivizumab during the 2005-2010 RSV seasons. Respiratory illness (RI) events were
documented monthly. RESULTS: The 7699 infants enrolled were premature (35
completed weeks gestational age, without any underlying medical illnesses;
n5237), had chronic lung disease/bronchopulmonary dysplasia (n646), hemo-
dynamically significant congenital heart disease (n766), or had other pre-existing
conditions such as neuromuscular impairments, Down syndrome, pulmonary or
airway malformations, immunocompromise or cystic fibrosis (n1050). The over-
all RIH rate was 6.0%. Premature infants had a significantly lower rate (4.1%) than
the other groups (range 8.7% -11.5%; B-0.912, df1, p0.005). The overall RSVH
rate was 1.47% with significant differences between groups (range 1.22% - 2.46%;
222.606, df3, p0.0005). Apart from hospital length of stay, morbidities differed
significantly across the sub-groups during RSVH including number of ICU admis-
sions and length of stay, number ventilated and duration of intubation, number
requiring respiratory support and duration (all p0.05). CONCLUSIONS: Hospital-
ization rates for RI events and RSV illness were different across the groups. Com-
parisons with other registries indicate that RSVH rates are in the lower range over-
all (range 1.3 -8.1%); however, comparisons are difficult to establish as most studies
do not account for the varying lengths of observation that arise because infants are
enrolled at different times during the RSV season.
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PROPHYLAXIS IN PREMATURE INFANTS
Paes BA1, Li A2, Lanctot KL2, Mitchell I3
1McMaster University, Hamilton, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON,
Canada, 3University of Calgary, Calgary, AB, Canada
OBJECTIVES: Infants 33-35 completed weeks’ gestational age (GA) and those  32
weeks GA incur similar rates of respiratory syncytial virus hospitalization (RSVH)
and morbidities which targets them as risk groups for RSV prophylaxis in current
international pediatric advisory statements. We examined immunization regi-
mens, compliance and outcomes of premature infants who received palivizumab
within the Canadian Registry Database (CARESS). METHODS: Neonatal and demo-
graphic data were collected from infants receiving 1 dose of palivizumab during
the 2006-2010 RSV seasons across 29 recruitment sites. Respiratory illness (RI)
events were captured monthly. Premature infants’ 32 weeks GA without pre-
existing medical disorders (Group 1) was compared to a similar moderate-high risk
group 33-35 completed weeks GA (Group 2) who received prophylaxis. RESULTS:
4819 patients were analyzed (Group 1, n3746; Group 2, n1073). Mean GA: 30.0
3.1 versus 34.22.0. The groups were similar for proportion of Caucasians, mothers’
who smoked daily and during pregnancy, history of atopy and number of multiples
in the family. There were significant differences (Group 1, Group 2; p0.005) in:
mean birth weight (g) (1445606 versus 2142521), proportion of males (54.3%
versus 63.1%), and number with siblings (54.2% versus 74.6%), siblings in daycare
(13.9% versus 35.0%), 2 household smokers (9.9% versus 14.0%) and  5 individ-
uals living in the household (22.7% versus 44.0%). Group 1 had significantly more
complicated neonatal courses. Overall infants received 91.9%30.7% of expected
number of injections. Group 1 received more injections (3.91.7 versus 3.51.6;
p0.005) and had higher compliance rates (92.8% versus 88.9%; p0.005). Respec-
tive RI and RSVH rates (4.5% versus 3.4%; hazard ratio0.852, p0.385) and (1.30%
versus 1.3%; hazard ratio1.233, p0.543) were similar. CONCLUSIONS: Overall
compliance with RSV prophylaxis in the premature population is high and despite
the higher number of palivizumab doses in infants 32 weeks GA, group RI and
RSVH rates were similar.
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OBJECTIVES: To compare palivizumab utilization and compliance in infants who
meet standard indications for RSV prophylaxis versus those with pre-existing
medical disorders within the Canadian Registry Database (CARESS). METHODS: A
prospective, observational registry of infants across 29 sites who received at least 1
dose of palivizumab during the 2006-2010 RSV seasons. Neonatal and demographic
data were collected from the parent/caregiver at enrollment. Data on palivizumab
utilization, compliance, and outcomes related to respiratory illness (RI) events
were collected monthly. Premature infants’ 35 completed weeks’ gestational age
(GA) without medical conditions who met standard approval criteria for palivi-
zumab (Group 1) were compared to infants with underlying medical illnesses
(Group 2). RESULTS: 5832 patients were analyzed (Group 1, n4880; Group 2,
n952). The two groups were similar in terms of gender (male: 56.4% versus 55.6%;
p0.829). Group 2 infants included Down syndrome (n193, 20.3%), upper airway
anomalies (n178, 18.7%), pulmonary disorders (n127, 13.3%), cystic fibrosis
(n117, 12.3%), neuromuscular impairment (n78, 8.2%), multiple system disor-
ders (n57, 6.0%), cardiac disorders (n22, 2.3%), immunocompromise (n17,
1.8%), and miscellaneous (n163, 17.1%). From 2006-2010, the proportion of Group
2 infants receiving prophylaxis increased 3.4-fold from 5.6% (69/1224) to 19.1%
(462/2413). Overall, Group 2 infants were older at enrollment (10.2  9.2 versus 3.5
 3.1 months, p0.005), had a significantly higher GA (35.9  6.0 versus 31.0  5.4
completed weeks, p0.005) and had significantly higher RI (9.0% versus 4.2%, p0.0
05) and RSV hospitalization (2.35% versus 1.32%, p0.003) rates. A lower proportion
of Group 2 infants were compliant with treatment (69.4% versus 72.6%, p0.048).
There were no serious adverse events directly related to palivizumab.
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CONCLUSIONS: Results imply that infants with underlying medical disorders that
are not specifically approved for prophylaxis by advisory bodies and current posi-
tion statements are at significant risk for hospitalization with respiratory illness
and RSV infections and may benefit from immunization.
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TREATMENT PATTERNS AND ASSOCIATED CLINICAL AND ECONOMIC
OUTCOMES OF WOMEN TREATED WITH HORMONE THERAPY
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OBJECTIVES: Compare clinical, economic outcomes among women treated with
hormone therapy (HT) with different treatment patterns. METHODS: We con-
ducted a retrospective database analysis using commercial enrollees from a large
US health plan from 2002 to 2010. HT initiators during the identification period
from 2005 to 2008 were included. The first HT prescription date was the index date.
Women aged 40 and older, having no evidence of pregnancy during the follow-up
period were selected. Continuous enrollment for 3 years pre- and 2 years post-
index was required. Patients were divided into groups based on HT initiation
(Group A: No menopause diagnosis; Group B: within 1 year of diagnosis; Group C:
1-2 years after diagnosis; Group D: 2-3 years after diagnosis). Propensity score
matching (PSM) was used to adjust baseline differences in age, region, medication
type, prescription fills, and pre-index costs and utilizations. Group B was a refer-
ence group (patients with earliest treatment after menopause diagnosis).
RESULTS: Among 14,008 eligible patients, 8,228 were included in group A, 2,418 in
group B, 1,491 in group C, and 1,871 in group D. After comparing A and B using PSM,
2,418 patients from each group were matched. Group A was more likely to have
osteoporosis, post-menopausal osteoporosis, hysterectomy, outpatient visits, and
had a lower medication persistence ratio (MPR) than Group B. A total of 1480 pa-
tients were matched when comparing groups C and B. Group C was more likely to
use bisphosphonates. After comparing groups D and B, 1,713 patients were
matched. Group D used more bisphosphonates and was more likely to have os-
teopenia and higher pharmacy costs. CONCLUSIONS: HT initiators within 1 year
had fewer comorbidities than HT initiators 3 years or more, following menopause
diagnosis. Compared to HT initiators after 1 year, but within 3 years of menopause
diagnosis, HT initiators within 1 year of diagnosis used fewer bisphosphonates.
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OBJECTIVES: In Hungary there are 10 institutes doing in vitro fertilization (IVF). The
aim of the study was perform a data analyzis of the efficiency in an eleven-year
period of Hungary involving all of the institutes’ data. METHODS: The database of
the Hungarian National Health Insurance Fund Administration (NHIFA), the only
health care financing agency in Hungary, was taken for the study. The analysis
covers an 11 years period between 2000 to 2010. IVF success rate was defined as the
proportion of number of live births and the number of IVF treatments. RESULTS: A
total of 71,634 IVF treatments were done between 2000 and 2011 in the 10 institutes.
50 % of the IVF treatments were done from the age of 30 to 36. The total number of
live births was 25,468. The number of single deliveries was 21,400 (84 %), twins 3779
(14.8 %), triplet 284 (1.1 %) and quadruplet 5 (0.02 %). The overall 11 year IVF success
rate was 35.6 %. The success rate showed significant differences among IVF centers
in a range of 31-49 %. The two largest IVF centres had a market share of 60.9 % and
their success rate was 38.4 % and 34.3 % respectively. The highest efficiency was at
the age of 34 (43.1 % birth rate). CONCLUSIONS: The mean of the IVF efficiency was
35.6 % in Hungary in the last 11 years. The best result was in the group of the patient
at the age of 30-36. The efficiency could be increased if the selection of the patients
were defined more precisely.
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OBJECTIVES: Present research aims at impact assessment of a two-year individu-
alized sports-recreational training programme performed regularly in relation to
living profile, self-rated health and salutogenetic sense of coherence (SOC).
METHODS: Enrolling volunteers participating weekly in sports and recreational
trainings for various reasons (health preservation, body toning etc.) were assessed
between 2008 and 2010 (n106, aged 17-61, woman73). Their health and wellness
status was continuously controlled, and duration, type and difficulty of trainings
were determined accordingly. At the beginning and at the end of the programme
status and changes were assessed by Optimal Life Profile (OLP) worked out by
Renger and colleagues, Antonovsky’s SOC-scale, the 4-grade self assessment of
health and Hennenhofer-Heil’s vegetative lability index (VELA). Data were ana-
lyzed by paired Wilcoxon-test and multivariate logistic regression model.
RESULTS: Compared to health and wellness status before the training programme
a significantly positive change could be demonstrated both in dimensions of OLP
and on VELA and SOC-scales. The global indices in all cases were p0.001 according
to the Wilcoxon-test. Age, sex, weekly regularity and duration of trainings were the
independent variables in the multivariate logistic regression model. The probabil-
ity of improving general health status was not influenced by any of the predictors,
however, the chance of improving vegetative lability was significantly greater
among women (p0.012, OR 5,5, CI95% 1,4-8,3), and predominantly increased in
those attending the trainings more times a week or for a longer duration. The
likelihood of enhancing sense of coherence was also present in women (p0.034,
OR3,2 CI95% 1,2 - 6,4). CONCLUSIONS: Individualized and controlled sports and
recreational training has proved to have a positive impact on general health status,
and optimal life profile in people aged 18-61 with no respect to age or sex. It has
enhanced the individual’s sense of coherence that positively affects many aspects
of life.
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OBJECTIVES: Our aim was to prove the effects of pregnancy on gait and maintain-
ing balance. METHODS: Gait and balance testing was performed on 20 young adult
- and 21 healthy pregnant women during 3 trimesters. Bretz stabilometer was used
to determine balance ability and gait parameters. During stabilometer measure-
ments static balance was examined with Romberg test while dynamic balance with
8 programs on a stabilometer. Duration of swing phase, rate of double-limb sup-
port, foot angle and step width were determined during gait study. Allocation of
patients was non randomized. Statistical data were calculated according to mean,
standard deviation, Fisher’s exact test, Student’s t-test methods and the results
were considered to be significant at p0.05. RESULTS: Gait of pregnant women
proved to be slower than that of the control group (p0,046), but the duration of
step-cycle decreased during the course of pregnancy. Duration of swing phase in
the first trimester is shorter compared to the control group (p0,040). The rate of
double-limb support to the total step-cycle showed an increase (p0,023) the third
trimester with the control group was compared. Foot angle of pregnant women in
the first trimester was bigger than that of the control group (p0,029). Pregnant
women’s step width in the first trimester was smaller as compared to the control
group (p0,002). Step width of pregnant women compared in the first and third
trimesters revealed a significant increase (p0,049). The difference in average re-
sults of Romberg with opened and closed eyes tests was not significant. Examina-
tion of dynamic balance showed significant difference between the results of
young adults women and pregnant women (p0,05). Examination data obtained
during the 1st and 3rd trimesters showed a significant improvement (p0,05) in
balance ability as pregnancy progressed. CONCLUSIONS: Our study revealed that
gait kinematics and balance changed during pregnancy.
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OBJECTIVES: The aim was to investigate changes of balance maintenance ability in
different trimesters and during menopause. METHODS: Investigation was per-
formed at the Department of Obstetrics and Gynaecology, Faculty of Medicine,
University of Pécs. Bretz stabilometer was used to determine balance- and coordi-
nation abilities. Static balance was measured with opened- and closed eyes Rom-
berg-test while dynamic balance was examined with the help of I. and II. pro-
grammes of the measuring instrument. The total number of examined subjects’
was 60: 20 young adults, 20 pregnant women (follow-up was performed in the 1st,
2nd and 3rd trimesters) and 20 women in menopause. Those suffering from severe
locomotor disorders, neurological and internal diseases, in the control group with
the existence of gestation and pathological pregnancy were closed out. Statistical
data were calculated according to (mean, standard deviation, range, F-test and
Student’s methods T-probe) MS Excel 2003.RESULTS:Comparison of survey results
of static balance did not show significant difference in the three groups. During the
survey of dynamic balance in the 1st programme significant improvement was
observed analyzing the results of young adults and pregnant women (p0,05).
Comparing the results in case of young adults and in menopause (p0,05) as well as
in groups of pregnant women and in menopause (p0,05) a definite impairment
was observed. In the 2nd programme on the basis of the results in the 4th sub-
programme a significantly worse performance was measured in menopause
(p0,05). CONCLUSIONS: Measurement results proved that in major stages of life,
with ageing, balance ability decreases. In our case, on the basis of survey data in the
1st and 3rd trimesters it is proved that with the progression of trimesters balance
ability significantly improves.
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PATIENTS WITH BPH IN FRANCE: RESULTS AT SIX MONTHS WITH
PHYTOTHERAPY VERSUS OTHER TREATMENTS
Perrin P1, Auges M2, Rahhali N2, Taieb C2
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OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower
urinary tract (LUT) suggestive of benign prostatic hypertrophy (BPH) using medical
treatment under actual conditions of use. METHODS: A pragmatic cohort patients
treated medically, was followed up for 6 months, using 3 questionnaires: IPSS and
SF12. RESULTS:A total of 182 patients under medical treatment were assessed; 146
patients were treated with phytotherapy, versus 36 patients on “other treatments”.
At inclusion, the patients treated with Serenoa Repens (hexanic extract) versus
other treatments” were different on the following characteristics: age, time since
diagnosis, IPSS score, physical and mental dimension of the SF12. The “change
from baseline” for the scores of the IPSS and SF12 self-assessment questionnaires
between the 2 treatment groups was compared. A linear model was used. We
observed an improvement in the IPSS score from 6 weeks. We were not able to
demonstrate a significant difference between the 2 treatment groups concerning
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